Previous 10 | Next 10 |
Shares of DexCom (NASDAQ: DXCM) were falling 5.2% lower as of 11:15 a.m. ET on Friday after sinking as much as 10.9% earlier in the day. The decline came after the diabetes-care technology company announced its second-quarter financial results after the market close on Thursday. ...
Avaya Holdings ( AVYA ) -23% on disappointing Q3 prelim results. Roku ( ROKU ) -21% as analysts rush to downgrade following Q2 miss, weak guidance. DexCom ( DXCM ) -13% on Q2 results. Intel ( INTC ) -12% on Q2 results. Cr...
Image source: The Motley Fool. DexCom (NASDAQ: DXCM) Q2 2022 Earnings Call Jul 28, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: DexCom (DXCM) Q2 2022 Earnings Call Transcript
DexCom, Inc. (DXCM) Q2 2022 Earnings Conference Call July 28, 2022, 4:30 PM ET Company Participants Sean Christensen - Investor Relations Kevin Sayer - Chairman, President and CEO Jereme Sylvain - Chief Financial Officer Conference Call Participants R...
The following slide deck was published by DexCom, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: DexCom, Inc. 2022 Q2 - Results - Earnings Call Presentation
DexCom ( NASDAQ: DXCM ) stock fell 7.1% to $80.85 after hours Thursday, as the diabetes medical device maker reported Q2 earnings that missed estimates. DXCM posted Q2 non-GAAP EPS of $0.17 which missed expectations by $0.02. Its Q2 revenue of $696.2M also missed b...
DexCom press release ( NASDAQ: DXCM ): Q2 Non-GAAP EPS of $0.17 misses by $0.02 . Revenue of $696.2M (+17.0% Y/Y) misses by $13.13M . Shares -7% . Non-GAAP Gross Profit Margin of approximately 65% Non-GAAP Operating Margin of approximately 16% ...
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2022. Second Quarter 2022 Financial Highlights: Revenue grew 17% versus the same quarter of the prior year to $696.2 million on a reported basis and 16% on an orga...
DexCom ( NASDAQ: DXCM ) is scheduled to announce Q2 earnings results on Thursday, July 28th, after market close. The consensus EPS Estimate is $0.19 (-75.0% Y/Y) and the consensus Revenue Estimate is $709.33M (+19.2% Y/Y). Over the last 2 years, DXCM has beaten EPS e...
Don't let DexCom 's (NASDAQ: DXCM) drop of 38% this year fool you: This business is teeming with growth, and it's still fully capable of being a great long-term investment, especially starting this week. The medical device manufacturer will report its second-quarter earnings after t...
News, Short Squeeze, Breakout and More Instantly...
2024-07-04 10:00:00 ET Growth-oriented investors have experienced a bit of a roller-coaster ride over the past few years. Many companies in the "growth stock" category were struggling just two years ago, but in the bull market we are now experiencing, they're delivering very different resul...
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2024 financial results after market close on Thursday, July 25, 2024. Management will hold a conference call to review the company's second quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the...